Literature DB >> 16421286

Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2).

Xiao-Yan Chu1, John R Strauss, Michele A Mariano, Jing Li, Deborah J Newton, Xiaoxin Cai, Regina W Wang, Jocelyn Yabut, Dylan P Hartley, David C Evans, Raymond Evers.   

Abstract

The multidrug resistance protein Mrp2 is an ATP-binding cassette (ABC) transporter mainly expressed in liver, kidney, and intestine. One of the physiological roles of Mrp2 is to transport bilirubin glucuronides from the liver into the bile. Current in vivo models to study Mrp2 are the transporter-deficient and Eisai hyperbilirubinemic rat strains. Previous reports showed hyperbilirubinemia and induction of Mrp3 in the hepatocyte sinusoidal membrane in the mutant rats. In addition, differences in liver cytochrome P450 and UGT1a levels between wild-type and mutant rats were detected. To study whether these compensatory mechanisms were specific to rats, we characterized Mrp2(-/-) mice. Functional absence of Mrp2 in the knockout mice was demonstrated by showing increased levels of bilirubin and bilirubin glucuronides in serum and urine, a reduction in biliary excretion of bilirubin glucuronides and total glutathione, and a reduction in the biliary excretion of the Mrp2 substrate dibromosulfophthalein. To identify possible compensatory mechanisms in Mrp2(-/-) mice, the expression levels of 98 phase I, phase II, and transporter genes were compared in liver, kidney, and intestine of male and female Mrp2(-/-) and control mice. Unlike in Mrp2 mutant rats, no induction of Mrp3 in Mrp2(-/-) mice was detected. However, Mrp4 mRNA and protein in liver and kidney were increased approximately 6- and 2-fold, respectively. Phenotypic analysis of major cytochrome P450-mediated activities in liver microsomes did not show differences between wild-type and Mrp2(-/-) mice. In conclusion, Mrp2(-/-) mice are a new valuable tool to study the role of Mrp2 in drug disposition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421286     DOI: 10.1124/jpet.105.098665

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.

Authors:  Vandana Megaraj; Takashi Iida; Paiboon Jungsuwadee; Alan F Hofmann; Mary Vore
Journal:  Drug Metab Dispos       Date:  2010-07-19       Impact factor: 3.922

2.  Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.

Authors:  J A Sprowl; V Gregorc; C Lazzari; R H Mathijssen; W J Loos; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

3.  N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.

Authors:  Lipeng Wang; Markos Leggas; Mamta Goswami; Philip E Empey; Patrick J McNamara
Journal:  Drug Metab Dispos       Date:  2008-09-17       Impact factor: 3.922

4.  Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.

Authors:  Andrea N Edginton; Eric I Zimmerman; Aksana Vasilyeva; Sharyn D Baker; John C Panetta
Journal:  Cancer Chemother Pharmacol       Date:  2016-04-06       Impact factor: 3.333

Review 5.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

6.  Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Regulate the Disposition of Acacetin Glucuronides.

Authors:  Huangyu Jiang; Jia Yu; Haihui Zheng; Jiamei Chen; Jinjun Wu; Xiaoxiao Qi; Ying Wang; Xinchun Wang; Ming Hu; Lijun Zhu; Zhongqiu Liu
Journal:  Pharm Res       Date:  2017-04-18       Impact factor: 4.200

Review 7.  Drug-drug interaction studies: regulatory guidance and an industry perspective.

Authors:  Thomayant Prueksaritanont; Xiaoyan Chu; Christopher Gibson; Donghui Cui; Ka Lai Yee; Jeanine Ballard; Tamara Cabalu; Jerome Hochman
Journal:  AAPS J       Date:  2013-03-30       Impact factor: 4.009

8.  Novel Hg2+-induced nephropathy in rats and mice lacking Mrp2: evidence of axial heterogeneity in the handling of Hg2+ along the proximal tubule.

Authors:  Rudolfs K Zalups; Lucy Joshee; Christy C Bridges
Journal:  Toxicol Sci       Date:  2014-08-21       Impact factor: 4.849

9.  Citrobacter rodentium Infection Inhibits Colonic P-glycoprotein Expression.

Authors:  Mitul Patel; Anoop Kumar; Dulari Jayawardena; Shubha Priyamvada; Arivarasu N Anbazhagan; Waddah A Alrefai; Ravinder K Gill; Pradeep K Dudeja; Seema Saksena
Journal:  Gene Rep       Date:  2019-10-31

Review 10.  Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology.

Authors:  Nazzareno Ballatori; Suzanne M Krance; Rosemarie Marchan; Christine L Hammond
Journal:  Mol Aspects Med       Date:  2008-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.